Search

Your search keyword '"Shepherd, Frances A."' showing total 1,940 results

Search Constraints

Start Over You searched for: Author "Shepherd, Frances A." Remove constraint Author: "Shepherd, Frances A."
1,940 results on '"Shepherd, Frances A."'

Search Results

107. Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

109. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

110. Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada

116. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

117. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population

120. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer

121. Automating Access to Real-World Evidence

122. Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.

124. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

127. Molecular heterogeneity of non‐small cell lung carcinoma patient‐derived xenografts closely reflect their primary tumors

129. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.

134. sj-docx-1-tam-10.1177_17588359221112696 – Supplemental material for The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

135. sj-docx-1-tam-10.1177_17588359221126151 – Supplemental material for Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy

136. sj-docx-1-cix-10.1177_11769351221136056 – Supplemental material for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts

143. Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials

144. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors

145. Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection

146. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system

148. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

149. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

150. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy

Catalog

Books, media, physical & digital resources